GEN Exclusives

More »

GEN News Highlights

More »
Oct 2, 2008

Rotarix Launch Results in $10M Payment to Celldex

  • Celldex Therapeutics received a milestone payment of $10 million from Paul Capital Healthcare, triggered by GlaxosmithKline’s launch of Rotarix® in the U.S.

    Earlier this year Celldex merged with Avant Immunotherapeutics, and late last month Avant changed its name to Celldex. Avant licensed the Rotarix technology to  GSK in 1997. The vaccine was originally developed at Cincinnati Children's Hospital Medical Center.

    "In purchasing a portion of Celldex's Rotarix royalty stream, Paul Capital Healthcare has helped Celldex to monetize a previously under-appreciated asset," said John Leone, a partner at Paul Capital Healthcare. "The U.S. approval and launch of Rotarix validate our assessment of the product's value and Celldex's contribution to its development. "

    Rotarix is an oral live-attenuated human rotavirus vaccine, developed for the prevention of rotavirus gastroenteritis by mimicking the protective effects of natural human rotavirus infection.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?